papapanda schreef op 1 juni 2021 13:57:
In Summary
• Our products address unmet medical needs in therapeutic areas with large total addressable
market opportunities (~$2.7B in PONV rescue, >$1.5B in procedural sedation)
• The team is making tremendous commercial progress despite a very challenging operating
environment due to the global pandemic
• We have seen a great response from customers in the early stages of launch adding our
products to formulary with positive customer feedback on both products so far
• While the environment remains very dynamic, we believe we should be able to benefit from a
relaxation of restrictions and a rebound in procedural volumes in the second half of this year
• We believe we have the right team, with the right experience to continue to drive the successful
commercial launch for both products this year